ClinicalTrials.gg
Not yet recruitingNCT07645950KOKORO01Updated Nov 12, 2026

Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy

An observational study in Pediatric Oncology, Radiotherapy and Parent, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Not yet recruiting at 1 site in France. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Observational

How we know

Updated Nov 12, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
6
Ages
4 Years and older
Sex
All
01

Study summary

Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the child and their parents. Companion robots represent an innovative avenue for patient support, but they have never been evaluated in the context of radiotherapy. This study examines the effect of MIROKI, the first social robot capable of communication through a Large Multimodal Model (LMM), on children's state anxiety during radiotherapy. An experimental single-case design (SCED) will compare phases with and without the robot (withdrawal/reversal), both in the waiting room and in the irradiation bunker. The primary outcome variable is anxiety, assessed in several ways: through questionnaires at the beginning and end of treatment; through an objective measure of cardiac activity (heart rate in bpm) during the radiotherapy session, with or without the MIROKI robot; and through an observational grid assessing the child's behavior. The intensive repeated measure (bpm) constitutes the preferred variable in this SCED design, while behavioral observation and anxiety questionnaires will support interpretation. The results could pave the way for reducing sedation and improving the overall care pathway in pediatric radiotherapy.

02

Conditions studied

  • Pediatric Oncology
  • Radiotherapy
  • Parent
03

In context

Lead sponsor

Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants will be recruited from the pediatric radiotherapy unit at Montpellier Cancer Institute (ICM).During the initial consultation to initiate radiotherapy treatment at ICM, the investigator physician will present the KOKORO-01 study. They will answer all questions regarding its procedures and will provide the parents or legal representative with the information sheet and consent form. Parents or the legal representative will have at least one week to consider participation, during which they may ask any questions they wish.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children aged 4 to 18 years, distributed across the following age groups: 4-7 years, 8-12 years, and 13-18 years.
  2. Child with an indication for radiotherapy treatment at ICM.
  3. Child who speaks French.
  4. Child accompanied by a parent or legal guardian who agrees to participate in the study and provide consent.
  5. Child covered by the French national health insurance system.

Exclusion criteria

Exclusion Criteria:

6. Child with a diagnosed neurodevelopmental disorder as a comorbidity. 7. Child with postoperative cognitive sequelae that make interaction during care difficult (e.g., language impairment). 8. Total body irradiation. 9. Child under legal protection, unable to express assent, or presenting major difficulties in understanding the study information. Parent Inclusion Criteria

  1. Parent of a child enrolled in the study.
  2. Able to speak French.
  3. Willing to participate in the study. Parent Exclusion Criteria

1. Parents or legal representatives under legal protection, or presenting an inability to consent or to understand the study information, making it impossible to provide free and for the minor's participation.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
6 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To evaluate the immediate intra-individual effect of MIROKI on a physiological marker of anxiety in children undergoing radiotherapy.

    The child's anxiety level measured through an objective assessment of heart rate (bpm sensor).

    Time frame: During the treatment, across the 6 radiotherapy sessions

Secondary outcomes

  1. Evaluate the immediate intra-individual effect of MIROKI in children on: Psychological distress level

    Distress questionnaire (PedsQL 3.0 Cancer Module score, Varni et al.)

    Time frame: administered before the start of treatment and after completion of treatment

  2. Evaluate the immediate intra-individual effect of MIROKI in children on development of attachment and reassurance

    Daily distress VAS (Peds-DTRS score, Patel et al., 2011, 2021) and standardized real-time observation using an observational grid.

    Time frame: Before, during, and after treatment

  3. Evaluate the satisfaction with care (radiotherapy at ICM) at the end of treatment

    Post-treatment interview (thematic and lexico-metric analysis).

    Time frame: At the end of treatment

  4. Evaluate the impact of MIROKI on the radiotherapy process: Setup time during sessions in the radiotherapy room

    Time frame: From the beginning to the end of the treatment course

  5. Evaluate the impact of MIROKI on parents: - Anxiety level - Satisfaction with care at the end of treatment - Experience of the radiotherapy process at the end of treatment

    * Anxiety score (GAD-7, Spitzer et al., 2006) * Parent-child relationship quality score (CPRS, Pianta et al., 1992) During treatment: \- Daily anxiety VAS (daily DT score, Leclair et al., 2016; NCCN, 2025) After treatment: \- Assessment of the radiotherapy experience and satisfaction with care with the robot, using the parent interview grid

    Time frame: Before the start , during and after the treatment,

07

Study locations

1 site
  • Julien Welmant
    Montpellier, Herault 34298, France
08

References and documents

Related links

Individual participant data

Plan to share: Yes — All data will be available after publication of the results in peer-reviewed revues, and in national and international meetings. It includes all de-identified participants' data, the study protocol, the statistical analysis plan and the clinical study report. The corresponding author will provide data and datasets generated and/or analyzed during the study upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Access to study data upon written detailed request sent to ICM, from 6 months until 5 years after publication of summary data.

Access criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 12, 2026
StartEst.
Dec 2026was Jul 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Dec 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Jul 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645950
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Aurore MOUSSION
Contact
drci-icm105@icm.unicancer.fr
0467613102 ext. +33
Julien, Welmant
principal investigator · ICM Co. Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion